<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02582814</url>
  </required_header>
  <id_info>
    <org_study_id>D1695C00001</org_study_id>
    <nct_id>NCT02582814</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM</brief_title>
  <official_title>A Clinical Pharmacology and Long Term Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With Type 1 Diabetes Who Have Inadequate Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll eligible subjects into a long-term safety study (Part B).

      Japanese male and female patients with T1DM and age 18 to 75 years, with inadequate glycemic
      control on insulin defined as HbA1c ≥ 7.5% and ≤ 10.5% at screening visit. As a condition of
      enrollment, subjects must be on a total daily insulin dose of ≥ 0.3 U/kg/day for at least 3
      months prior to the screening visit. The study design of Part B is a randomized, open-label,
      2 arm, parallel-group design. 140 Japanese subjects in total will be randomized in a 1:1
      ratio into one of the two treatment arms; dapagliflozin 5 mg or dapagliflozin 10 mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 26, 2015</start_date>
  <completion_date type="Actual">June 15, 2017</completion_date>
  <primary_completion_date type="Actual">June 15, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Adverse Event Summary</measure>
    <time_frame>From baseline to 52 weeks</time_frame>
    <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>From baseline to 52 weeks</time_frame>
    <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diabetic Ketoacidosis (DKA)</measure>
    <time_frame>From baseline to 52 weeks</time_frame>
    <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs (Heart Rate)</measure>
    <time_frame>From baseline to 52 weeks</time_frame>
    <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECGs</measure>
    <time_frame>From baseline to 52 weeks</time_frame>
    <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Measures, Urine Test Results (Any Marked Abnormality)</measure>
    <time_frame>From baseline to 52 weeks</time_frame>
    <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs (Blood Pressure)</measure>
    <time_frame>From baseline to 52 weeks</time_frame>
    <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in HbA1c</measure>
    <time_frame>From baseline to 24/52 weeks</time_frame>
    <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Percent Change From Baseline in Total Daily Insulin Dose</measure>
    <time_frame>From baseline to 24/52 weeks</time_frame>
    <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Percent Change From Baseline in Body Weight</measure>
    <time_frame>From baseline to 24/52 weeks</time_frame>
    <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in Glycoalbumin</measure>
    <time_frame>From baseline to 24/52 weeks</time_frame>
    <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in Average Daily Glucose Measured by 6-point SMBG</measure>
    <time_frame>From baseline to 24/52 weeks</time_frame>
    <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in Post-prandial Glucose Measured by 6-point SMBG</measure>
    <time_frame>From baseline to 24/52 weeks</time_frame>
    <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent Without Severe Hypoglycemia</measure>
    <time_frame>From baseline to 24/52 weeks</time_frame>
    <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent</measure>
    <time_frame>From baseline to 24/52 weeks</time_frame>
    <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving HbA1c &lt; 7.0 Percent</measure>
    <time_frame>From baseline to 24/52 weeks</time_frame>
    <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in SBP in Subjects With Baseline SBP/DBP &gt;= 140/90 mmHg</measure>
    <time_frame>From baseline to 24/52 weeks</time_frame>
    <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>dapagliflozin 5mg + insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dapagliflozin tablet 5mg + adjustable insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dapagliflozin 10mg + insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dapagliflozin tablet 10mg + adjustable insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 5 mg</intervention_name>
    <description>Dapagliflozin, a blood glucose lowering drug. Oral dose</description>
    <arm_group_label>dapagliflozin 5mg + insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg</intervention_name>
    <description>Dapagliflozin, a blood glucose lowering drug. Oral dose</description>
    <arm_group_label>dapagliflozin 10mg + insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Written Informed Consent

          -  Diagnosis of T1DM. In addition, the following criteria also needs to be met; Central
             laboratory test of C-peptide &lt; 0.7 ng/mL

          -  Insulin use for at least 12 months prior to the enrolment per subject report or
             medical records and Method of insulin administration (MDI or CSII) must have been
             unchanged for at least 3 months prior to the enrolment per subject report or medical
             records. Subjects must be taking a total daily insulin dose of ≥ 0.3 U/kg/day for at
             least 3 months prior to the enrolment. If on MDI insulin administration subject must
             be on ≥ 3x injections per day.

          -  Japanese men and women

          -  Screening Visit: Central laboratory HbA1c ≥ 7.5% and ≤ 10.5%

          -  BMI ≥ 20.0 kg/m² at visit 1

          -  Age 18 to 75 years, inclusive

        Exclusion Criteria:

        - Target Disease Exceptions History of T2DM Maturity onset diabetes of young (MODY) Any
        anti-hyperglycemic agent use, other than α-GI or insulin, within 1 month prior to the
        enrolment.

        Use of thiazolidinediones within 6 months prior to the enrolment History of DKA requiring
        medical intervention within 1 month prior to the enrolment History of hospital admission
        for glycemic control (either hyperglycemia or hypoglycemia) within 1 month prior to the
        enrolment

          -  Medical History and Concurrent Diseases Malignancy within 5 years of the enrolment
             (with the exception of treated basal cell or treated squamous cell carcinoma) History
             of bladder cancer History of radiation therapy to the lower abdomen or pelvis at any
             time

          -  Physical and Laboratory Test Findings Aspartate aminotransferase (AST) &gt; 3x upper
             limit of normal (ULN) Alanine aminotransferase (ALT) &gt; 3x ULN Serum total bilirubin
             (TB) &gt; 2.0 mg/dL (34.2 μmol/L) Estimated GFR (eGFR) by the Japanese Society of
             Nephrology formula ≤ 45 mL/min/1.73m2 Hemoglobin ≤ 11.0 g/dL (110 g/L) for men;
             hemoglobin ≤ 10.0 g/dL (100 g/L) for women.

        Positive for hepatitis B surface antigen or anti-hepatitis C virus antibody Abnormal Free
        T4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aizu Wakamatsu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Funabashi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamamatsu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hirosaki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ise-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koriyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumamoto-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kunitachi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minato-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oita-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Otsu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjyuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suita-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tsukuba-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3797&amp;filename=D1695C00001_SAP_Redacted.pdf</url>
    <description>D1695C00001_SAP_redacted</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3797&amp;filename=D1695C00001_CSP_redacted.pdf</url>
    <description>D1695C00001_CSP_redacted</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <results_first_submitted>June 5, 2018</results_first_submitted>
  <results_first_submitted_qc>January 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2019</results_first_posted>
  <last_update_submitted>January 14, 2019</last_update_submitted>
  <last_update_submitted_qc>January 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese patients with type 1 diabetes with inadequate glycemic control on insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02582814/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 14, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02582814/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dapagliflozin 5mg + Insulin</title>
          <description>dapagliflozin tablet 5mg + adjustable insulin</description>
        </group>
        <group group_id="P2">
          <title>Dapagliflozin 10mg + Insulin</title>
          <description>dapagliflozin tablet 10mg + adjustable insulin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study-specific withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized set</population>
      <group_list>
        <group group_id="B1">
          <title>Dapagliflozin 5mg + Insulin</title>
          <description>dapagliflozin tablet 5mg + adjustable insulin</description>
        </group>
        <group group_id="B2">
          <title>Dapagliflozin 10mg + Insulin</title>
          <description>dapagliflozin tablet 10mg + adjustable insulin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.7" spread="12.85"/>
                    <measurement group_id="B2" value="48.9" spread="12.93"/>
                    <measurement group_id="B3" value="48.3" spread="12.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.28" spread="3.635"/>
                    <measurement group_id="B2" value="24.66" spread="2.806"/>
                    <measurement group_id="B3" value="24.97" spread="3.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of T1DM</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.60" spread="8.420"/>
                    <measurement group_id="B2" value="15.94" spread="10.328"/>
                    <measurement group_id="B3" value="15.27" spread="9.409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.43" spread="0.711"/>
                    <measurement group_id="B2" value="8.40" spread="0.715"/>
                    <measurement group_id="B3" value="8.42" spread="0.711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-peptide</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 0.1 ng/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 0.1 ng/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Adverse Event Summary</title>
        <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
        <time_frame>From baseline to 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Adverse Event Summary</title>
          <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events</title>
              <category_list>
                <category>
                  <title>At least one events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Adverse Events</title>
              <category_list>
                <category>
                  <title>At least one events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <title>At least one events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation</title>
              <category_list>
                <category>
                  <title>At least one events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <title>At least one events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hypoglycemia</title>
        <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
        <time_frame>From baseline to 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia</title>
          <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Hypoglycemia Episodes</title>
              <category_list>
                <category>
                  <title>At least one events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Hypoglycemia</title>
              <category_list>
                <category>
                  <title>At least one events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented Symptomatic Hypoglycemia</title>
              <category_list>
                <category>
                  <title>At least one events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymptomatic Hypoglycemia</title>
              <category_list>
                <category>
                  <title>At least one events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable Symptomatic Hypoglycemia</title>
              <category_list>
                <category>
                  <title>At least one events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relative Hypoglycemia</title>
              <category_list>
                <category>
                  <title>At least one events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diabetic Ketoacidosis (DKA)</title>
        <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
        <time_frame>From baseline to 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Diabetic Ketoacidosis (DKA)</title>
          <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite DKA</title>
              <category_list>
                <category>
                  <title>At least one events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possible DKA</title>
              <category_list>
                <category>
                  <title>At least one events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unlikely DKA</title>
              <category_list>
                <category>
                  <title>At least one events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in HbA1c</title>
        <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
        <time_frame>From baseline to 24/52 weeks</time_frame>
        <population>All available post-baseline data were included in analysis. Nubmer of observations at each time point is presented in the table below.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in HbA1c</title>
          <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
          <population>All available post-baseline data were included in analysis. Nubmer of observations at each time point is presented in the table below.</population>
          <units>percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" lower_limit="-0.66" upper_limit="-0.38"/>
                    <measurement group_id="O2" value="-0.66" lower_limit="-0.80" upper_limit="-0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" lower_limit="-0.50" upper_limit="-0.15"/>
                    <measurement group_id="O2" value="-0.36" lower_limit="-0.53" upper_limit="-0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Percent Change From Baseline in Total Daily Insulin Dose</title>
        <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
        <time_frame>From baseline to 24/52 weeks</time_frame>
        <population>All available post-baseline data were included in analysis. Nubmer of observations at each time point is presented in the table below.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Percent Change From Baseline in Total Daily Insulin Dose</title>
          <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
          <population>All available post-baseline data were included in analysis. Nubmer of observations at each time point is presented in the table below.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.30" lower_limit="-18.55" upper_limit="-11.92"/>
                    <measurement group_id="O2" value="-15.14" lower_limit="-18.43" upper_limit="-11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.27" lower_limit="-15.92" upper_limit="-8.46"/>
                    <measurement group_id="O2" value="-13.13" lower_limit="-16.77" upper_limit="-9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Percent Change From Baseline in Body Weight</title>
        <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
        <time_frame>From baseline to 24/52 weeks</time_frame>
        <population>All available post-baseline data were included in analysis. Nubmer of observations at each time point is presented in the table below.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Percent Change From Baseline in Body Weight</title>
          <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
          <population>All available post-baseline data were included in analysis. Nubmer of observations at each time point is presented in the table below.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.88" lower_limit="-4.74" upper_limit="-3.02"/>
                    <measurement group_id="O2" value="-5.26" lower_limit="-6.11" upper_limit="-4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.25" lower_limit="-5.29" upper_limit="-3.21"/>
                    <measurement group_id="O2" value="-5.96" lower_limit="-6.98" upper_limit="-4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in Glycoalbumin</title>
        <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
        <time_frame>From baseline to 24/52 weeks</time_frame>
        <population>All available post-baseline data were included in analysis. Nubmer of observations at each time point is presented in the table below.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in Glycoalbumin</title>
          <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
          <population>All available post-baseline data were included in analysis. Nubmer of observations at each time point is presented in the table below.</population>
          <units>percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" lower_limit="-2.83" upper_limit="-1.70"/>
                    <measurement group_id="O2" value="-2.63" lower_limit="-3.22" upper_limit="-2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" lower_limit="-2.18" upper_limit="-0.77"/>
                    <measurement group_id="O2" value="-1.68" lower_limit="-2.41" upper_limit="-0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in Average Daily Glucose Measured by 6-point SMBG</title>
        <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
        <time_frame>From baseline to 24/52 weeks</time_frame>
        <population>All available post-baseline data were included in analysis. Nubmer of observations at each time point is presented in the table below.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in Average Daily Glucose Measured by 6-point SMBG</title>
          <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
          <population>All available post-baseline data were included in analysis. Nubmer of observations at each time point is presented in the table below.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.37" lower_limit="-15.80" upper_limit="-2.94"/>
                    <measurement group_id="O2" value="-15.06" lower_limit="-21.62" upper_limit="-8.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.62" lower_limit="-18.62" upper_limit="-4.62"/>
                    <measurement group_id="O2" value="-12.93" lower_limit="-19.99" upper_limit="-5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in Post-prandial Glucose Measured by 6-point SMBG</title>
        <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
        <time_frame>From baseline to 24/52 weeks</time_frame>
        <population>All available post-baseline data were included in analysis. Nubmer of observations at each time point is presented in the table below.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in Post-prandial Glucose Measured by 6-point SMBG</title>
          <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.</description>
          <population>All available post-baseline data were included in analysis. Nubmer of observations at each time point is presented in the table below.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.33" lower_limit="-11.18" upper_limit="6.51"/>
                    <measurement group_id="O2" value="-10.08" lower_limit="-19.04" upper_limit="-1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.40" lower_limit="-15.45" upper_limit="2.64"/>
                    <measurement group_id="O2" value="-5.24" lower_limit="-14.32" upper_limit="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent Without Severe Hypoglycemia</title>
        <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin</description>
        <time_frame>From baseline to 24/52 weeks</time_frame>
        <population>Subjects with non-missing HbA1c baseline and Week24/52 (LOCF) values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent Without Severe Hypoglycemia</title>
          <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin</description>
          <population>Subjects with non-missing HbA1c baseline and Week24/52 (LOCF) values were included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" lower_limit="48.8" upper_limit="72.0"/>
                    <measurement group_id="O2" value="61.3" lower_limit="49.4" upper_limit="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" lower_limit="39.4" upper_limit="63.1"/>
                    <measurement group_id="O2" value="41.3" lower_limit="30.1" upper_limit="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent</title>
        <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin</description>
        <time_frame>From baseline to 24/52 weeks</time_frame>
        <population>Subjects with non-missing HbA1c baseline and Week24/52 (LOCF) values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent</title>
          <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin</description>
          <population>Subjects with non-missing HbA1c baseline and Week24/52 (LOCF) values were included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2" lower_limit="50.1" upper_limit="73.2"/>
                    <measurement group_id="O2" value="66.7" lower_limit="54.8" upper_limit="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" lower_limit="39.4" upper_limit="63.1"/>
                    <measurement group_id="O2" value="45.3" lower_limit="33.8" upper_limit="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Achieving HbA1c &lt; 7.0 Percent</title>
        <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin</description>
        <time_frame>From baseline to 24/52 weeks</time_frame>
        <population>Subjects with non-missing HbA1c baseline and Week24/52 (LOCF) values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Achieving HbA1c &lt; 7.0 Percent</title>
          <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin</description>
          <population>Subjects with non-missing HbA1c baseline and Week24/52 (LOCF) values were included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="3.9" upper_limit="18.5"/>
                    <measurement group_id="O2" value="5.3" lower_limit="1.5" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="2.2" upper_limit="15.1"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.3" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in SBP in Subjects With Baseline SBP/DBP &gt;= 140/90 mmHg</title>
        <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin</description>
        <time_frame>From baseline to 24/52 weeks</time_frame>
        <population>Subjects with baseline SBP &gt;= 140mmHg and/or baselien DBP &gt;= 90mmHg were included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in SBP in Subjects With Baseline SBP/DBP &gt;= 140/90 mmHg</title>
          <description>To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin</description>
          <population>Subjects with baseline SBP &gt;= 140mmHg and/or baselien DBP &gt;= 90mmHg were included in analysis.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" lower_limit="-11.2" upper_limit="-0.3"/>
                    <measurement group_id="O2" value="-12.0" lower_limit="-19.0" upper_limit="-5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" lower_limit="-15.1" upper_limit="-4.5"/>
                    <measurement group_id="O2" value="-14.2" lower_limit="-20.7" upper_limit="-7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Signs (Heart Rate)</title>
        <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
        <time_frame>From baseline to 52 weeks</time_frame>
        <population>Subjects with both non-missing baseline and non-missing Week 52 were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs (Heart Rate)</title>
          <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
          <population>Subjects with both non-missing baseline and non-missing Week 52 were included.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="10.07"/>
                    <measurement group_id="O2" value="0.4" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ECGs</title>
        <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
        <time_frame>From baseline to 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>ECGs</title>
          <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <title>NORMAL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ABNORMAL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NOT REPORTED</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <title>NORMAL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ABNORMAL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NOT REPORTED</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Measures, Urine Test Results (Any Marked Abnormality)</title>
        <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
        <time_frame>From baseline to 52 weeks</time_frame>
        <population>Subjects with non-missing post-baseilne measurements were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Measures, Urine Test Results (Any Marked Abnormality)</title>
          <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
          <population>Subjects with non-missing post-baseilne measurements were included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit (&gt; 55%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (&gt; 18g/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (&gt;1.5 x ULN pre Rx)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatin kinase (&gt; 5x ULN)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (&lt;= 13 mEq/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P (&lt;=1.8/2.1mg/dL for age&lt;=/&gt;65)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UACR (&gt; 1800mg/g)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Signs (Blood Pressure)</title>
        <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
        <time_frame>From baseline to 52 weeks</time_frame>
        <population>Subjects with both non-missing baseline and non-missing Week 52 were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>dapagliflozin tablet 5mg + adjustable insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>dapagliflozin tablet 10mg + adjustable insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs (Blood Pressure)</title>
          <description>To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.</description>
          <population>Subjects with both non-missing baseline and non-missing Week 52 were included.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline in SBP(mmHg) at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="11.41"/>
                    <measurement group_id="O2" value="-2.9" spread="12.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline in DBP(mmHg) at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="8.21"/>
                    <measurement group_id="O2" value="-1.0" spread="7.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year. Non-serious adverse event (AE): onset on or after the 1st day of dose up to on or prior to the last day of dose plus 4 days. Serious AE: onset on or after the 1st day of dose up to on or prior to the last day of dose plus 30 days</time_frame>
      <desc>Only hypoglycemia/ DKA reported as a serious adverse event are included.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dapagliflozin 5mg + Insulin</title>
          <description>dapagliflozin tablet 5mg + adjustable insulin</description>
        </group>
        <group group_id="E2">
          <title>Dapagliflozin 10mg + Insulin</title>
          <description>dapagliflozin tablet 10mg + adjustable insulin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>VITREOUS HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC FUNCTION ABNORMAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOGLYCAEMIC COMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DENTAL CARIES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>THIRST</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="39" subjects_affected="25" subjects_at_risk="76"/>
                <counts group_id="E2" events="44" subjects_affected="32" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>KETOSIS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" events="15" subjects_affected="7" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" events="12" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>POLLAKIURIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>A clinical pharmacology and long-term safety study</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+819039706431 ext 4669</phone>
      <email>Yu.Shimizuishi@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

